These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22487725)

  • 1. Is the measurement of anti-Müllerian hormone essential?
    Usta T; Oral E
    Curr Opin Obstet Gynecol; 2012 Jun; 24(3):151-7. PubMed ID: 22487725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).
    La Marca A; Sighinolfi G; Radi D; Argento C; Baraldi E; Artenisio AC; Stabile G; Volpe A
    Hum Reprod Update; 2010; 16(2):113-30. PubMed ID: 19793843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of anti-Mullerian hormone measurement in a routine IVF program.
    Gnoth C; Schuring AN; Friol K; Tigges J; Mallmann P; Godehardt E
    Hum Reprod; 2008 Jun; 23(6):1359-65. PubMed ID: 18387961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical applications of anti-Müllerian hormone in evaluating ovarian reserve functions].
    Yu M; Deng CY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):114-9. PubMed ID: 19317075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measurement of serum AMH levels in gynecology: indications and limits].
    Streuli I; Cantero-Perez P; Miserez-Zaugg C
    Rev Med Suisse; 2013 Oct; 9(403):1954-6, 1958. PubMed ID: 24245018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients.
    Aleyasin A; Aghahoseini M; Mokhtar S; Fallahi P
    Acta Med Iran; 2011; 49(11):715-20. PubMed ID: 22131240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anti-Müllerian hormone in female fertility and infertility - an overview.
    Grynnerup AG; Lindhard A; Sørensen S
    Acta Obstet Gynecol Scand; 2012 Nov; 91(11):1252-60. PubMed ID: 22646322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti mullerian hormone (AMH)--is it a new reliable marker of the ovarian reserve? Its role in predicting the ovarian response in assisted reproductive technology (ART)].
    Alshiek JA; Lessing JB; Amit A; Azem F
    Harefuah; 2012 Jul; 151(7):416-20, 435. PubMed ID: 23002694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
    Tremellen K; Zander-Fox D
    Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles.
    Tolikas A; Tsakos E; Gerou S; Prapas Y; Loufopoulos A
    Hum Fertil (Camb); 2011 Dec; 14(4):246-53. PubMed ID: 22088130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-mullerian hormone as a marker of ovarian reserve.
    Tremellen KP; Kolo M; Gilmore A; Lekamge DN
    Aust N Z J Obstet Gynaecol; 2005 Feb; 45(1):20-4. PubMed ID: 15730360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients.
    Sahmay S; Guralp O; Aydogan B; Cepni I; Oral E; Irez T
    Gynecol Endocrinol; 2013 May; 29(5):440-3. PubMed ID: 23461296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
    Yates AP; Rustamov O; Roberts SA; Lim HY; Pemberton PW; Smith A; Nardo LG
    Hum Reprod; 2011 Sep; 26(9):2353-62. PubMed ID: 21672928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the utility of anti-Müllerian hormone in female infertility.
    Grynnerup AG; Lindhard A; Sørensen S
    Curr Opin Obstet Gynecol; 2014 Jun; 26(3):162-7. PubMed ID: 24722366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.
    Tal R; Seifer DB; Khanimov M; Malter HE; Grazi RV; Leader B
    Am J Obstet Gynecol; 2014 Jul; 211(1):59.e1-8. PubMed ID: 24593938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.